Federated Hermes’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.2M Buy
98,315
+1,036
+1% +$198K 0.03% 482
2026
Q1
$17.8M Sell
97,279
-33,889
-26% -$6.24M 0.03% 498
2025
Q4
$23.1M Buy
131,168
+6,246
+5% +$1.02M 0.04% 427
2025
Q3
$17.5M Buy
124,922
+4,645
+4% +$628K 0.03% 449
2025
Q2
$15.1M Buy
120,277
+17,069
+17% +$2.13M 0.03% 488
2025
Q1
$14.1M Buy
103,208
+1,805
+2% +$258K 0.03% 478
2024
Q4
$15.5M Sell
101,403
-1,181
-1% -$199K 0.03% 457
2024
Q3
$19.9M Sell
102,584
-358
-0.3% -$74.9K 0.04% 428
2024
Q2
$23.9M Buy
102,942
+218
+0.2% +$47.4K 0.06% 365
2024
Q1
$22.2M Buy
102,724
+2,576
+3% +$603K 0.05% 394
2023
Q4
$25.9M Sell
100,148
-4,320
-4% -$1.06M 0.06% 334
2023
Q3
$26.8M Buy
104,468
+44,328
+74% +$11.9M 0.07% 303
2023
Q2
$17.1M Sell
60,140
-2,731
-4% -$813K 0.04% 423
2023
Q1
$17.5M Buy
62,871
+250
+0.4% +$69.2K 0.04% 428
2022
Q4
$17.3M Sell
62,621
-72,028
-53% -$20.3M 0.05% 417
2022
Q3
$36M Sell
134,649
-177,323
-57% -$37.7M 0.11% 238
2022
Q2
$63.6M Buy
311,972
+91,985
+42% +$18.8M 0.17% 153
2022
Q1
$46.3M Buy
219,987
+150,537
+217% +$32.7M 0.1% 241
2021
Q4
$16.7M Buy
69,450
+64,015
+1,178% +$16.5M 0.03% 532
2021
Q3
$1.54M Sell
5,435
-152
-3% -$49.8K ﹤0.01% 1124
2021
Q2
$1.94M Sell
5,587
-1,792
-24% -$543K ﹤0.01% 1110
2021
Q1
$2.06M Sell
7,379
-61,203
-89% -$16.5M ﹤0.01% 1094
2020
Q4
$16.8M Sell
68,582
-43,012
-39% -$11.1M 0.03% 512
2020
Q3
$31.7M Sell
111,594
-91,748
-45% -$25.6M 0.07% 299
2020
Q2
$54.4M Buy
203,342
+58,606
+40% +$17.6M 0.13% 177
2020
Q1
$45.8M Sell
144,736
-14,130
-9% -$4.29M 0.13% 170
2019
Q4
$47.1M Sell
158,866
-161,853
-50% -$44.9M 0.11% 229
2019
Q3
$74.7M Buy
320,719
+54,821
+21% +$12.8M 0.18% 127
2019
Q2
$62.2M Buy
265,898
+51,424
+24% +$11.9M 0.15% 154
2019
Q1
$50.7M Sell
214,474
-31,893
-13% -$10M 0.13% 181
2018
Q4
$74.1M Buy
246,367
+21,274
+9% +$6.79M 0.2% 105
2018
Q3
$79.5M Buy
225,093
+221,374
+5,953% +$76.2M 0.19% 119
2018
Q2
$1.08M Sell
3,719
-30
-0.8% -$8.43K ﹤0.01% 1267
2018
Q1
$1.03M Sell
3,749
-58
-2% -$18K ﹤0.01% 1219
2017
Q4
$1.21M Buy
3,807
+102
+3% +$32.7K ﹤0.01% 1152
2017
Q3
$1.16M Sell
3,705
-902
-20% -$267K ﹤0.01% 1160
2017
Q2
$1.25M Sell
4,607
-3,768
-45% -$996K ﹤0.01% 1125
2017
Q1
$2.29M Sell
8,375
-3,251
-28% -$919K 0.01% 856
2016
Q4
$3.3M Sell
11,626
-12,183
-51% -$3.61M 0.01% 688
2016
Q3
$7.45M Sell
23,809
-4,717
-17% -$1.4M 0.02% 484
2016
Q2
$6.9M Buy
28,526
+2,702
+10% +$712K 0.02% 480
2016
Q1
$6.72M Sell
25,824
-18,101
-41% -$4.78M 0.02% 487
2015
Q4
$13.5M Sell
43,925
-423,936
-91% -$122M 0.04% 372
2015
Q3
$137M Buy
467,861
+25,599
+6% +$8.45M 0.44% 46
2015
Q2
$179M Buy
442,262
+516
+0.1% +$207K 0.54% 36
2015
Q1
$187M Sell
441,746
-49,528
-10% -$19.5M 0.57% 30
2014
Q4
$167M Buy
491,274
+37,694
+8% +$12.2M 0.52% 37
2014
Q3
$150M Buy
453,580
+33,801
+8% +$11.1M 0.48% 40
2014
Q2
$132M Sell
419,779
-4,158
-1% -$1.25M 0.42% 44
2014
Q1
$130M Buy
423,937
+751
+0.2% +$238K 0.43% 44
2013
Q4
$118M Sell
423,186
-12,705
-3% -$3.29M 0.41% 47
2013
Q3
$105M Sell
435,891
-31,059
-7% -$6.95M 0.4% 47
2013
Q2
$100M Buy
+466,950
New +$99.8M 0.4% 50

Other funds holding BIIB

Federated Hermes's BIIB Position: Q2 2026 in Review

Federated Hermes increased its Biogen (BIIB) stake by 1.1% in Q2 2026, buying an estimated $198K and bringing the position to 98,315 shares worth $21.2M. The position accounts for 0.03% of the portfolio, ranked #482.

Federated Hermes first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $187M in Q1 2015. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Federated Hermes held 98,315 shares of Biogen worth $21.2M as of Q2 2026.
  • Federated Hermes bought 1,036 Biogen shares in Q2 2026, an estimated $198K.
  • Biogen made up 0.03% of Federated Hermes's portfolio in Q2 2026, its #482 holding.
  • Federated Hermes first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • Federated Hermes's Biogen position peaked at $187M in Q1 2015.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.